TrialSignal
Clinical trial intelligence report
A Phase I Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML)
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT00074750-Jul 28, 2026
NCT ID
NCT00074750
Status
TERMINATED
Phase
Phase 1
Sponsor
M.D. Anderson Cancer Center
Executive brief
Investment-Ready Snapshot
DT388GMCSF represents a novel therapeutic approach targeting refractory Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML) through a fusion protein mechanism. The market for AML therapies is significant, with ongoing demand for innovative treatments due to high unmet needs in relapsed and refractory cases. The competitive landscape includes established therapies and emerging agents, necessitating a thorough diligence process to assess DT388GMCSF's potential positioning and differentiation. The trial's termination due to slow accrual raises concerns regarding market viability and investor interest, suggesting a need for strategic reevaluation or potential partnership opportunities to enhance recruitment and development pathways.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT00074750
Indication
Acute Myelogenous Leukemia
Modality
small molecule
Target
Granulocyte-macrophage colony-stimulating factor (GM-CSF) receptors on leukemic cells, utilizing diphtheria toxin for targeted cell destruction.
Intervention
DTGM
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.